DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Osteoporosis and Dental Implant

Information source: Charite University, Berlin, Germany
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis

Intervention: alendronate once weekly 70mg (Drug); placebo (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Charite University, Berlin, Germany

Official(s) and/or principal investigator(s):
Dieter Felsenberg, Prof. D.r, Study Chair, Affiliation: Leader of the center for muscle and bone research, Charité

Overall contact:
Dieter Felsenberg, Prof. Dr., Phone: +490384453046, Email: dieter.felsenberg@charite.de


The purpose of this study is to evaluate the influence of alendronate therapy on the wound healing after dental implants in patients with osteoporosis.

Clinical Details

Official title: Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Dental CT


Minimum age: 60 Years. Maximum age: 75 Years. Gender(s): Female.


Inclusion Criteria:

- Postmenopausal women > 2 years after menopause

- Age between 60 and 75 years

- Possibility to insert a dental implant

- Osteoporosis as defined by WHO criteria (intervention group), or women without

osteoporosis / osteopenia (non-intervention group) Exclusion Criteria:

- Pathological findings in the jaw bone

- Chronic inflammatory rheumatoid disease

- Bisphosphonate treatments during the last 12 months

- Inflammatory or metabolic bone disease, excluding osteoporosis

- Systemic corticosteroid treatments of more than one month within previous 12 months

- Severe diseases with life expectancy less than one year or expectation of rapid

worsening within one year

Locations and Contacts

Dieter Felsenberg, Prof. Dr., Phone: +490384453046, Email: dieter.felsenberg@charite.de

Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin, Berlin 12200, Germany; Recruiting
Dieter Felsenberg, Prof. Dr., Phone: +493084453046
Hendrikje Boerst, Dipl. Wiss. org., Phone: +493084454745, Email: hendrikje.boerst@charite.de
Dieter Felsenberg, Prof. Dr., Principal Investigator
Anton ° Friedman, Dr., Sub-Investigator
Additional Information

Starting date: January 2004
Last updated: August 1, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017